Suven Life Sciences Limited
₹146.07-0.79%Feb 27, 3:45 PM IST
SUVEN•Health Technology•Pharmaceuticals: Major
Current Price
₹146.07-0.79%
Feb 27, 3:45 PM ISTMarket Cap₹3,368.89 Cr
Market Cap₹3,368.89 Cr
Business Overview
Suven Life Sciences Limited operates through 1 main business divisions including Drug Discovery & Development.
Business Hierarchy Structure for Suven Life Sciences Limited
- Suven Life Sciences Limited
- Drug Discovery & Development
- Lead Clinical-Stage Assets
- Masupirdine (5-HT6 receptor antagonist)
- Samelisant (Histamine 3 receptor inverse agonist)
- Ropanicant (α4β2 antagonist)
- Other Clinical-Stage Assets
- Usmarapride (5-HT4 receptor agonist)
- SUVN-I6107 (True muscarinic M1 positive allosteric modulator)
- SUVN-M8036 (Serotonin and dopamine modulator)
- SUVN-D1044 (5-HT4 receptor agonist)
- Research-Stage Assets
- M4 PAM (Psychosis)
- P2X7 antagonists (Pain & Inflammation)
- Dual 5-HT2A antagonist & 5-HT1A agonist (Psychosis & Depression)
- 5-HT1A agonists (Treatment-Resistant Depression)
- Dual 5-HT2A antagonist & SSRI (Bipolar Disorders & Schizophrenia)
- M1 PAM (Gastrointestinal Disorders)
- Lead Clinical-Stage Assets
- Drug Discovery & Development